Dr. Eyad Abu-Isa received his undergraduate degree at the University of Michigan College of Engineering, graduating with top honors in chemical engineering. He then went to University of Michigan Medical School and graduated with honors in 2006. He did both his internship in internal medicine and radiation oncology residency at University of Michigan, serving as chief resident in radiation oncology in 2010-2011.
Dr. Abu-Isa focuses most of his time on patient care and practices at Providence Cancer Center in Southfield and Assarian Cancer Center in Novi. He enjoys treating all disease sites and has been researching the role of high activity low dose rate brachytherapy in the setting of recurrent and unresectable cancers.
Outside of the clinic, Dr. Abu-Isa enjoys spending time with his family and racing in endurance events. He has completed four full-distance Ironman events, achieved All World status, and completed 15+marathons.
Areas of Interest
- Use of low-dose rate brachytherapy in high risk and recurrent cancers
- All disease sites
Honors & Awards
- Top Doctors: Hour Detroit, 2016
- Residency, University of Michigan, Radiation Oncology, 2011
- MD, University of Michigan Medical School, 2006
- BSE, Chemical Engineering, University of Michigan, 2002
- Board certification: Radiation Oncology
Selected from 9 publications
- Shumway DA, Abu-Isa E, Soto DE, Do TT, Jagsi R. Depigmentation within the radiation field in patients With Vitiligo. Int J Radiat Oncol Biol Phys. 94(2):421-2. doi: 10.1016/j.ijrobp.2015.10.018, 2016.
- Liss AL, Abu-Isa EI, Jawad MS, Feng FY, Vance SM, Winfield RJ, Narayana V, Sandler HM, McLaughlin PW, Hamstra DA, Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: The impact of Gleason pattern 5. Brachytherapy. 14(4):502-10. doi: 10.1016/j.brachy.2015.02.389, 2015.
- Haidar A, Arekapudi S, DeMattia F, Abu-Isa E, Kraut M, High-grade undifferentiated small round cell sarcoma with t(4;19)(q35;q13.1) CIC-DUX4 fusion: emerging entities of soft tissue tumors with unique histopathologic features--a case report and literature review. Am J Case Rep. 16:87-94. doi: 10.12659/AJCR.892551, 2015. Review.
- Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. Cancer. 119(3):681-90. doi: 10.1002/cncr.27784, 2013.
- Vainshtein J, Abu-Isa E, Olson KB, Ray ME, Sandler HM, Normolle D, Litzenberg DW, Masi K, Pan C, Hamstra DA. Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy. Radiat Oncol. 7:82. doi: 10.1186/1748-717X-7-82, 2012.